BLLN BillionToOne, Inc.

QT52

NASDAQ·Healthcare·Medical - Diagnostics & Research·USA

Latest market price

113.32

-1.52-1.32%

Overview Short InterestFilings

BLLNQT52BillionToOne, Inc.·NASDAQ

Overview Short InterestFilings

113.32-1.32%

Earnings

Down 1.3% — Earnings due 2026-11-04 — pre-report positioning.

Medium confidence

Loading chart...

Signal & projected range

Insider open-market saleHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

SHC-2.94%$18.15 RDNT-0.22%$73.49 CDNA+22.22%$87.41 GRAL-9.75%$143.43 VCYT-4.14%$50.01 QGEN-0.24%$50.22 WGS-2.76%$69.06 ICLR-1.91%$211.36

Snapshot

Index	—	P/E	182.77	EPS (ttm)	0.62	Insider Own	14.21%	Shs Outstand	47.19M	Perf Week	5.15%

Market Cap	5.35B	Forward P/E	112.88	EPS next Y	1.00	Insider Trans	-5.72%	Shs Float	5.60M	Perf Month	7.15%

Enterprise Value	4.94B	PEG	4.75	EPS next Q	0.15			Short Float	52.34%	Perf Quarter	-17.48%

Income	34.00M	P/S	13.47	EPS this Y	621.93%			Short Ratio	4.34	Perf Half Y	46.24%

Sales	397.00M	P/B	9.96	EPS next Y	29.41%	ROA	4.59%	Short Interest	2.93M	Perf YTD	38.47%

Book/sh	11.38	P/C	9.74	EPS next 5Y	38.51%	ROE	7.87%	52W High	150.44 -24.67%	Perf Year	—

Cash/sh	11.63	P/FCF	162.04	EPS past 3/5Y	—	ROIC	6.33%	52W Low	61.96 82.89%	Perf 3Y	—

Dividend Est.	—	EV/EBITDA	96.77	Sales past 3/5Y	—	Gross Margin	71.27%	Volatility	4.17% 5.71%	Perf 5Y	—

Dividend TTM	—	EV/Sales	12.43	EPS Y/Y TTM	—	Oper. Margin	10.90%	ATR (14)	5.83	Perf 10Y	—

Dividend Ex-Date	—	Quick Ratio	11.31	Sales Y/Y TTM	89.95%	Profit Margin	8.43%	RSI (14)	59.48	Recom	2.20

Dividend Gr. 3/5Y	—	Current Ratio	11.69	EPS Q/Q	-55.88%	SMA20	9.23%	Beta	1.63	Target Price	126.00

Payout	0.00%	Debt/Eq	0.26	Sales Q/Q	62.69%	SMA50	9.16%	Rel Volume	0.72	Prev Close	114.84

Employees	713	LT Debt/Eq	0.26	Earnings	Nov 04	SMA200	17.51%	Avg Volume	651.44K	Price	113.32

IPO Date	Nov 06, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	-18.15% 0.17%	Net Debt/EBITDA	-8.08	Volume	468,077	Change	-1.32%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Oct-01-26	Reiterated	Guggenheim	Buy	$125 → $128
Sep-02-26	Initiated	Canaccord	Buy	$120
Jun-29-26	Reiterated	Guggenheim	Buy	$120 → $125
May-07-26	Reiterated	BTIG	Buy	$140 → $130
Mar-05-26	Reiterated	BTIG	Buy	$160 → $140
Jan-06-26	Initiated	Guggenheim	Buy	$120
Dec-01-25	Initiated	BTIG	Buy	$160
Dec-01-25	Initiated	Wells Fargo	Equal Weight	$110
Dec-01-25	Initiated	Stifel	Buy	$145
Dec-01-25	Reiterated	Piper Sandler		$150

Latest News· Times ET

Oct-29-26

Oct-29-2602:15PM

BillionToOne: New Kid On The Molecular Diagnostics Block Poised To Take Shareseekingalpha.com

07:35AM

Baxter International (BAX) Q3 Earnings and Revenues Surpass EstimatesYahoo

Oct-28-26

Oct-28-2611:06AM

BillionToOne (BLLN) Reports Next Week: Wall Street Expects Earnings Growthzacks.com

Oct-27-26

Oct-27-2608:05AM

BillionToOne to Participate in Two Upcoming Investor Conferencesglobenewswire.com

Oct-19-26

Oct-19-2604:22AM

Billiontoone (NASDAQ:BLLN) CEO Sells $516,184.50 in Stockdefenseworld.net

Oct-14-26

Oct-14-2608:05AM

BillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026globenewswire.com

Oct-12-26

Oct-12-2610:41PM

BillionToOne: A Molecular Diagnostics Stock With Strong Quality And GARP Credentialsseekingalpha.com

06:41PM

BillionToOne: A Molecular Diagnostics Stock With Strong Quality And GARP CredentialsSeekingAlpha

Oct-07-26

Oct-07-2607:52AM

Natera: Priced To Perfection Amidst Rising Competitive ThreatsSeekingAlpha

07:00AM

BillionToOne's Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Findsglobenewswire.com

Oct-02-26

Oct-02-2606:41AM

Billiontoone (NASDAQ:BLLN) Shares Down 4.6% After Insider Sellingdefenseworld.net

Oct-01-26

Oct-01-2606:09AM

Guggenheim Maintains Buy on BillionToOne, Raises Price Target to $128Benzinga

Sep-23-26

Sep-23-2602:09PM

Medicare Lab Fee Changes Impact BillionToOne, CareDx Differentlybenzinga.com

04:06AM

BillionToOne Stock Jumped 12% Yesterday. Here’s What the Streets Target.Yahoo

Sep-21-26

Sep-21-2608:56AM

BillionToOne SVP Sells 1,416 Sharesfool.com

Company

BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023
Total Revenue	397	305	153	72
Cost of Goods Sold Incl. D&A	113	97	72	54
Gross Profit	283	208	81	17
Selling, General and Administrative Excl. Other	181	143	91	64
Research and Development	59	49	37	22
Other Operating Expense	0	0	0	1
Operating Income	44	16	-47	-69
Interest Expense	0	0	2	3
Unusual Expense	—	—	—	—
Non-Operating Income (Expense)	-5	-8	8	-10
Net Income Before Taxes	39	8	-42	-83
Income Taxes	0	0	0	0
Consolidated Net Income	34	7	-42	-83
Net Income From Continuing Operations	38	7	-42	-83
Net Income	34	7	-42	-83
EPS (Recurring)	0.69	0.06	-0.93	-1.85
EPS (Basic, Before Extraordinaries)	0.69	0.06	-0.93	-1.85
EPS (Diluted)	0.62	0.06	-0.93	-1.85
EBITDA	51	20	-27	-73
Other After Tax Adjustments	—	—	—	—
Stock Option Compensation Expense	—	—	—	—
Price To Earnings Ratio	182.77	1,284.77	—	—
Price To Sales Ratio	13.13	12.34	—	—
Gross Margin	71.28	68.20	52.94	23.61
Operating Margin	11.08	5.25	-30.72	-95.83
Net Margin	8.56	2.30	-27.45	-115.28
Shares Outstanding	46	46	45	45
Market Capitalization	5,213	3,765	—	—
Operating Lease Expense	—	—	—	—

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Atay Oguzhan	Chairman and CEO	Oct 28 '26	Option Exercise	2.80	8,333	23,332	8,333	Oct 30
Atay Oguzhan	Chairman and CEO	Oct 28 '26	Sale	118.00	11,000	1,298,000	0	Oct 30
Lynch Thomas P.	Officer	Oct 13 '26	Option Exercise	8.65	2,000	17,300	10,700	Oct 19
Atay Oguzhan	Chairman and CEO	Oct 15 '26	Sale	100.23	5,150	516,188	0	Oct 16
Atay Oguzhan	Chairman and CEO	Oct 15 '26	Option Exercise	2.80	5,150	14,420	5,150	Oct 16
Atay Oguzhan	Chairman and CEO	Oct 14 '26	Sale	98.19	5,850	574,386	0	Oct 16
Atay Oguzhan	Chairman and CEO	Oct 14 '26	Option Exercise	2.80	3,183	8,912	3,183	Oct 16
Atay Oguzhan	Chairman and CEO	Oct 12 '26	Sale	94.31	19,334	1,823,450	0	Oct 14
Atay Oguzhan	Chairman and CEO	Oct 12 '26	Option Exercise	2.80	16,667	46,668	16,667	Oct 14
Lynch Thomas P.	Officer	Oct 08 '26	Option Exercise	8.65	8,000	69,200	8,700	Oct 13
Tsao David	Chief Technology Officer	Oct 05 '26	Sale	108.15	20,000	2,162,951	1,000	Oct 07
ten Bosch John Roderick	SVP of Laboratory Operations	Oct 05 '26	Sale	105.15	2,834	297,996	19,385	Oct 07
Tsao David	Chief Technology Officer	Oct 05 '26	Option Exercise	2.80	20,000	56,000	21,000	Oct 07
Atay Oguzhan	Chairman and CEO	Sep 28 '26	Sale	120.64	10,999	1,326,919	0	Sep 30
Atay Oguzhan	Chairman and CEO	Sep 28 '26	Option Exercise	2.80	8,333	23,332	8,333	Sep 30

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.